256
Views
40
CrossRef citations to date
0
Altmetric
Review

End of life care in chronic obstructive pulmonary disease: in search of a good death

&
Pages 11-29 | Published online: 07 Mar 2008

Figures & data

Figure 1 Definitions (CitationNHS Executive 1996; CitationDepartment of Health 2007).

Table 1 Symptom prevalence in advanced COPD (CitationSolano et al 2006)

Figure 2 Typical disease trajectories for progressive chronic illness. (a) Long-term limitation with intermittent acute episodes eg COPD. (b) Prolonged dwindling eg dementia. (c) Short period of decline eg cancer. (Adapted from Murray et al with permission from BMJ Publishing Group Ltd.).

Figure 2 Typical disease trajectories for progressive chronic illness. (a) Long-term limitation with intermittent acute episodes eg COPD. (b) Prolonged dwindling eg dementia. (c) Short period of decline eg cancer. (Adapted from Murray et al with permission from BMJ Publishing Group Ltd.).

Figure 3 World Health Organisation three step analgesic ladder (CitationWHO 1996). Non opioids include paracetamol and NSAIDs; weak opioids include codeine (approx. 1/10th potency of oral morphine) and tramadol (approx. 1/5th potency of oral morphine); strong opioids include morphine, oxycodone and fentanyl; adjuvants are additional drugs that can be used as part of pain management, such as secondary analgesics (eg. gabapentin for neuropathic pain) and drugs to control analgesic adverse effects.

Figure 3 World Health Organisation three step analgesic ladder (CitationWHO 1996). Non opioids include paracetamol and NSAIDs; weak opioids include codeine (approx. 1/10th potency of oral morphine) and tramadol (approx. 1/5th potency of oral morphine); strong opioids include morphine, oxycodone and fentanyl; adjuvants are additional drugs that can be used as part of pain management, such as secondary analgesics (eg. gabapentin for neuropathic pain) and drugs to control analgesic adverse effects.

Table 2 Major components of a good death (CitationSteinhauser et al 2000)

Table 3 Barriers to communication about end of life issues in COPD